• [³H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain
• <em>Anismus</em>-A Very Unusual Extrapyramidal Side Effect of Paliperidone Palmitate in an Adolescent with Schizo-Affective Disorder
• 3-Acetylpyridine-induced ataxic-like motor impairments are associated with plastic changes in the Purkinje cells of the rat cerebellum
• 3-Hydroxyanthranilic Acid Delays Paralysis in <em>Caenorhabditis elegans</em> Models of Amyloid-Beta and Polyglutamine Proteotoxicity
• 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms
• 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice
• 6-shogaol against 3-Nitropropionic acid-induced Huntington's disease in rodents: Based on molecular docking/targeting pro-inflammatory cytokines/NF-kappaB-BDNF-Nrf2 pathway
• A Rare Case of Phentermine-Related Tardive Dyskinesia
• Accuracy and replicability of identifying eyelid tremor as an indicator of recent cannabis smoking
• Activation of alpha-7 nicotinic acetylcholine receptor by tropisetron mitigates 3-nitropropionic acid-induced Huntington's disease in rats: Role of PI3K/Akt and JAK2/NF-kappaB signaling pathways
• Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
• Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
• Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats
• Alpha Alert: Utilization of Transdermal Clonidine for Refractory Agitation
• Amantadine use in the French prospective NS-Park cohort
• AMPK-mediated autophagy pathway activation promotes deltaFosB degradation to improve levodopa-induced dyskinesia
• An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders
• An Unexpected Phenomenon: A Case of Citalopram-Induced Dyskinesia
• Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association
• Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia
• Angiostrongylus cantonensis induces energy imbalance and dyskinesia in mice by reducing the expression of melanin-concentrating hormone
• Angiotensin-converting enzyme inhibition prevents l-dopa-induced dyskinesia in a 6-ohda-induced mouse model of Parkinson's disease
• Antagonism of metabotropic glutamate receptor type 5 prevents levodopa-induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence
• Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India
• Association of UGT1A6 gene polymorphisms with sodium valproate-induced tremor in patients with epilepsy
• Ataxia Telangiectasia patient-derived neuronal and brain organoid models reveal mitochondrial dysfunction and oxidative stress
• Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain
• Bidirectional regulation of levodopa-induced dyskinesia by a specific neural ensemble in globus pallidus external segment
• Brexpiprazole-related tardive dystonia in a young patient with schizophrenia: A case report
• Canine paroxysmal dyskinesia-a review
• Central Nervous System Adverse Reactions to Amantadine Intoxication: A Case Report and Analysis of JADER
• Clozapine Prescripers-Dogmatic or Pragmatic?
• Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review
• Copper enhances aggregational toxicity of mutant huntingtin in a Drosophila model of Huntington's Disease
• Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole
• Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest
• Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study
• Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development
• Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model
• Does botulinum toxin affect psycho-social aspects in dystonia?
• Dopa-responsive dystonia and paroxysmal dystonic attacks associated with <em>ATP1A3</em> gene variant
• Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis
• Effect of 3-nitropropionic acid on sirtuin gene expression in Sirt3 deficient mice
• Effect of Capsaicin on 3-NP-Induced Neurotoxicity: A Pre-Clinical Study
• Effectiveness of Continuous Dopaminergic Therapies in Parkinson's Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics
• Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats
• Effects of Intracerebral Aminophylline Dosing on Catalepsy and Gait in an Animal Model of Parkinson's Disease
• Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial
• Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study
• Enhancement of Haloperidol-Induced Catalepsy by GPR143, an l-DOPA Receptor, in Striatal Cholinergic Interneurons
• Evaluation and Management of Tremor
• Fenobam modulates distinct electrophysiological mechanisms for regulating excessive gamma oscillations in the striatum of dyskinetic rats
• Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression
• Flapping Tremor: Unraveling Asterixis-A Narrative Review
• Gabapentin-induced Multifocal Myoclonus
• Gastrodin Improves the Activity of the Ubiquitin-Proteasome System and the Autophagy-Lysosome Pathway to Degrade Mutant Huntingtin
• Glycine transporter-1 inhibition by NFPS promotes neuroprotection against striatal damage models
• Haloperidol-induced painless legs and moving toe syndrome in a schizophrenia patient: a case report
• Hand Dystonia after Focused Ultrasound Thalamotomy in Essential Tremor
• Hyperglycemia-induced hemichorea-hemiballismus syndrome - a systematic review
• Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia
• In Silico Prediction of Potential Inhibitors for Targeting RNA CAG Repeats via Molecular Docking and Dynamics Simulation: A Drug Discovery Approach
• Integrating Network Pharmacology, Transcriptomics to Reveal Neuroprotective of Curcumin Activate PI3K / AKT Pathway in Parkinson's Disease
• Intranasal delivery of liposome encapsulated flavonoids ameliorates l-DOPA induced dyskinesia in hemiparkinsonian mice
• IRL790 modulated striatal D1 neurons synaptic plasticity ameliorating levodopa-induced dyskinesia in mouse
• Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study
• Levofloxacin-Induced Oromandibular Dystonia in a 9-Year-Old Patient
• Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia
• Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database
• Neuroprotective effects of Shenghui decoction via inhibition of the JNK/p38 MAPK signaling pathway in an AlCl(3)-induced zebrafish (Danio rerio) model of Alzheimer's disease
• Nitrous Oxide-induced Myeloneuropathy Due to Recreational Abuse
• Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson's Disease: Dopa Worsening Dystonia
• Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease
• Pluripotent Stem Cells as a Preclinical Cellular Model for Studying Hereditary Spastic Paraplegias
• Putative Mechanism of Action of Trazodone-Related Oromandibular Dyskinesia
• Quercetin's Restorative Properties in Male Mice with 3-Nitropropionic Acid-induced Huntington-like Symptoms: Molecular Docking, Behavioral, and Biochemical Assessment
• Regulatory mechanism of miR-20a-5p in neuronal damage and inflammation in lipopolysaccharide-induced BV2 cells and MPTP-HCl-induced Parkinson's disease mice
• Relapse of Tardive Dyskinesia Following Successful Treatment With Amantadine: A Case Report
• Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease
• Serotonin as a biomarker of toxin-induced Parkinsonism
• Severity of Antipsychotic-Induced Cervical Dystonia Assessed by the Algorithm-Based Rating System
• Sleep deprivation induces late deleterious effects in a pharmacological model of Parkinsonism
• Small-molecule targeting PKM2 provides a molecular basis of lactylation-dependent fibroblast-like synoviocytes proliferation inhibition against rheumatoid arthritis
• Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
• Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice
• Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia
• The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease
• The Effect of Neuronal CoQ(10) Deficiency and Mitochondrial Dysfunction on a Rotenone-Induced Neuronal Cell Model of Parkinson's Disease
• The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease
• The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics
• The neuroprotective potential of magnesium in Parkinson's disease
• The Phenytoin Ataxia Enigma Unveiled ''A Case Report''
• The prevalence of non-troublesome dyskinesia in Parkinson's disease
• Trazodone-related oromandibular dyskinesia
• Trehalose prevents the formation of aggregates of mutant ataxin-3 and reduces soluble ataxin-3 protein levels in an SCA3 cell model
• Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol
• Tyrosinase inhibition prevents non-coplanar polychlorinated biphenyls and polybrominated diphenyl ethers-induced hyperactivity in developing zebrafish: Interaction between pigmentation and neurobehavior
• Unraveling belly dancer's dyskinesia and other puzzling diagnostic contortions: A narrative literature review
• Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
• Vigabatrin-associated hyperkinetic movements in two children with epileptic spasms: Case reports and video phenomenology description